A Phase Ia clinical trial to assess the safety and immunogenicity of MVA-EBO Z alone and a heterologous prime-boost immunisation with ChAd3-EBO Z and MVA-EBO Z in healthy UK volunteers

Trial Profile

A Phase Ia clinical trial to assess the safety and immunogenicity of MVA-EBO Z alone and a heterologous prime-boost immunisation with ChAd3-EBO Z and MVA-EBO Z in healthy UK volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs GSK 3390107A (Primary) ; MVA EBOZ vaccine Emergent BioSolutions (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2015 Planned End Date changed from 1 Dec 2015 to 22 Oct 2015 according to United Kingdom Clinical Research Network.
    • 10 Dec 2015 Status changed from recruiting to active, no longer recruiting according to United Kingdom Clinical Research Network.
    • 06 Nov 2015 Accrual to date is 92% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top